Dapirolizumab pegol
Sponsors
UCB Biopharma, UCB Biopharma SRL
Conditions
Systemic Lupus ErythematosusSystemic lupus erythematosus (SLE)
Phase 3
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
Enrolling by invitationNCT04976322
Start: 2021-07-27End: 2030-08-07Target: 760Updated: 2026-04-03
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
RecruitingCTIS2023-508191-11-00
Start: 2024-11-28Target: 111Updated: 2025-12-23
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus
Active, not recruitingCTIS2023-506368-14-00
Start: 2021-09-07Target: 255Updated: 2025-11-17